RE:RE:RE:News FlowNHP can benefir by learning/studing from Biosyent (RX business model)..
NHP is unique from RX as these are generic compound pills ( whereas RX typically licences smaller niche specialty branded pharma products, patented and may involve hardware, ... That said, if NHP could take just a few pages from the RX book it would be great:
-like keeping share dilution to a minimum,
-being frugal on all fronts of developement and operations,
-strong focus on reputation in the industry,
just to name a few Biosyent traits that helped its stock sky rocket... BTW if NPH can execute like RX has on their business model, the potential is scary, and like Dart says I better not say here because it might sound crazy...